James Shmerling Net Worth

James Shmerling biography

Dr. James E. Shmerling is Director of the company. He is a seasoned executive who has worked in leadership roles at several pediatric hospitals around the United States during his career. For over three decades, he has served in management roles at children’s hospitals across the country and is nationally recognized as a leader in issues concerning children’s health and wellness. Prior to joining Connecticut Children’s, Jim spent eight years as the Chief Executive Officer of Children’s Hospital Colorado. Before that, he was the Executive Director and Chief Executive Officer of the Monroe Carell Jr. Children’s Hospital at Vanderbilt from 2002 to 2007. Jim is a Fellow in the American College of Health Care Executives (ACHE). He is an adjunct faculty member in the Hospital Administration programs, University of Alabama at Birmingham.

How old is James Shmerling?

James Shmerling is 63, he's been the Director of Biostage since 2018. There are no older and 6 younger executives at Biostage.

What's James Shmerling's mailing address?

James's mailing address filed with the SEC is C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON, MA, 01746.

Insiders trading at Biostage

Over the last 9 years, insiders at Biostage have traded over $962,849 worth of Biostage stock and bought 1,593,581 units worth $3,804,230 . The most active insiders traders include David Green, Capital Llc Dst oraz Ronald J Packard. On average, Biostage executives and independent directors trade stock every 79 days with the average trade being worth of $217,604. The most recent stock trade was executed by Capital Llc Dst on 6 April 2023, trading 62,500 units of BSTG stock currently worth $375,000.

What does Biostage do?

Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.

Biostage executives and stock owners

Biostage executives and other stock owners filed with the SEC include:

• David Green,
  Director
• Dr. William L. Fodor Ph.D.,
  Chief Scientific Officer
• Yu Hong,
  Pres
• Thomas Robinson,
  Independent Director
• James Shmerling,
  Director
• Ting Li,
  Director
• Harout DerSimonian,
  Chief Scientific Officer
• James Mastridge,
  Interim Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
• Hong Yu,
  President
• Jason Jing Chen,
  Chairman of the Board
• Dr. Shunfu Hu Ph.D.,
  VP of Bus. Devel. & Operations
• Peter A. Pellegrino Jr.,
  Interim VP of Fin.
• David Green,
  CEO & Chairman
• Blaine H. Mc Kee,
  Director
• Saverio La Francesca,
  See Remarks
• John J Canepa,
  Director
• Thomas Mc Naughton,
  Chief Financial Officer
• John F Kennedy,
  Director
• James Joseph Mc Gorry,
  Chief Executive Officer
• William Fodor,
  Chief Scientific Officer
• Herman Sanchez,
  Director
• Xiaoyu Du,
  10% owner
• Matthew D Dallas,
  Director
• Wei Zhang,
  Director
• Jeffrey E Young,
  Director
• Peter M Chakoutis,
  Vice President of Finance
• Ronald J Packard,
  Director
• Capital Llc Dst,
  10% owner
• Jing Chen,
  
• Junli He,
  CEO
• Joseph Luis Jr Damasio,
  Chief Financial Officer